The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials

With data from three monotherapy baricitinib phase III randomized clinical trials (RCTs), we conducted a posthoc mediator analysis to assess whether changes in itch or skin severity mediated the treatment effect over placebo on changes in health‐related quality of life. In this analysis, baricitinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yosipovitch, Gil, Papp, Kim, Forman, Seth, Han, George, Waibel, Jill, Rueda, Maria J., Sun, Luna, Chen, Yun‐Fei, Goldblum, Orin, Pierce, Evangeline, Silverberg, Jonathan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322426/
https://www.ncbi.nlm.nih.gov/pubmed/35041213
http://dx.doi.org/10.1111/bjd.21015
_version_ 1784756300926681088
author Yosipovitch, Gil
Papp, Kim
Forman, Seth
Han, George
Waibel, Jill
Rueda, Maria J.
Sun, Luna
Chen, Yun‐Fei
Goldblum, Orin
Pierce, Evangeline
Silverberg, Jonathan I.
author_facet Yosipovitch, Gil
Papp, Kim
Forman, Seth
Han, George
Waibel, Jill
Rueda, Maria J.
Sun, Luna
Chen, Yun‐Fei
Goldblum, Orin
Pierce, Evangeline
Silverberg, Jonathan I.
author_sort Yosipovitch, Gil
collection PubMed
description With data from three monotherapy baricitinib phase III randomized clinical trials (RCTs), we conducted a posthoc mediator analysis to assess whether changes in itch or skin severity mediated the treatment effect over placebo on changes in health‐related quality of life. In this analysis, baricitinib demonstrated significant improvement in the Dermatology Life Quality Index for which itch mediated approximately half of the changes at weeks 4 and 16.[Image: see text]
format Online
Article
Text
id pubmed-9322426
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93224262022-07-30 The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials Yosipovitch, Gil Papp, Kim Forman, Seth Han, George Waibel, Jill Rueda, Maria J. Sun, Luna Chen, Yun‐Fei Goldblum, Orin Pierce, Evangeline Silverberg, Jonathan I. Br J Dermatol Correspondence With data from three monotherapy baricitinib phase III randomized clinical trials (RCTs), we conducted a posthoc mediator analysis to assess whether changes in itch or skin severity mediated the treatment effect over placebo on changes in health‐related quality of life. In this analysis, baricitinib demonstrated significant improvement in the Dermatology Life Quality Index for which itch mediated approximately half of the changes at weeks 4 and 16.[Image: see text] John Wiley and Sons Inc. 2022-04-21 2022-06 /pmc/articles/PMC9322426/ /pubmed/35041213 http://dx.doi.org/10.1111/bjd.21015 Text en © 2022 Eli Lilly and Company. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Correspondence
Yosipovitch, Gil
Papp, Kim
Forman, Seth
Han, George
Waibel, Jill
Rueda, Maria J.
Sun, Luna
Chen, Yun‐Fei
Goldblum, Orin
Pierce, Evangeline
Silverberg, Jonathan I.
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
title The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
title_full The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
title_fullStr The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
title_full_unstemmed The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
title_short The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
title_sort contribution of itch and skin severity improvements to the dermatology life quality index in patients with atopic dermatitis in baricitinib phase iii trials
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322426/
https://www.ncbi.nlm.nih.gov/pubmed/35041213
http://dx.doi.org/10.1111/bjd.21015
work_keys_str_mv AT yosipovitchgil thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT pappkim thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT formanseth thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT hangeorge thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT waibeljill thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT ruedamariaj thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT sunluna thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT chenyunfei thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT goldblumorin thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT pierceevangeline thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT silverbergjonathani thecontributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT yosipovitchgil contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT pappkim contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT formanseth contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT hangeorge contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT waibeljill contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT ruedamariaj contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT sunluna contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT chenyunfei contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT goldblumorin contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT pierceevangeline contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials
AT silverbergjonathani contributionofitchandskinseverityimprovementstothedermatologylifequalityindexinpatientswithatopicdermatitisinbaricitinibphaseiiitrials

Ejemplares similares